BLTE
Belite Bio, IncHealthcare · $6.7B market cap
Verdict
We can't put a fair value on BLTE right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow BLTE
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
1 of the investors we track holds BLTE. In Q2 2026, 1 opened a position. Who we track
Moves in Q2 2026
New position: Lee Ainslie
Insider activity
Since Sep 4, 2026: no open-market purchases and 38 sales worth $31.9M. Why purchases matter
Sales
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-08
Sold
$507K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-08
Sold
$908K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-08
Sold
$879K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-08
Sold
$806K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-08
Sold
$427K
Show all 38 salesShow fewer
Lin Yu-Hsin
Chief Executive Officer · 2026-09-08
Sold
$535K
Lin Yu-Hsin
Chief Executive Officer · 2026-09-08
Sold
$1.7M
Lin Yu-Hsin
Chief Executive Officer · 2026-09-08
Sold
$1.2M
Lin Yu-Hsin
Chief Executive Officer · 2026-09-08
Sold
$1.2M
Lin Yu-Hsin
Chief Executive Officer · 2026-09-08
Sold
$466K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$889K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$654K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$1.2M
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$343K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$1.2M
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$358K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$730K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$857K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$717K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$659K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$689K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$365K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$362K
Chuang Hao-Yuan
Chief Financial Officer · 2026-09-04
Sold
$294K
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$1.6M
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$810K
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$2.1M
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$114K
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$1.7M
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$573K
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$1.2M
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$1.5M
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$851K
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$1.2M
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$908K
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$623K
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$469K
Lin Yu-Hsin
Chief Executive Officer · 2026-09-04
Sold
$475K
About Belite Bio, Inc
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works